Main finding: There was no difference between medical therapy and placebo in reducing the incidence of POAG in OHT patients at moderate risk of developing POAG
Purpose: To evaluate the efficacy of reduction of intraocular pressure by dorzolamide in preventing or delaying primary open-angle glaucoma in patients affected by ocular hypertension
Study type: Randomized controlled trial
Condition: Ocular Hypertension
Participants: 30-80 yo, IOP 22-29 mmHg in at least 1 eye, open angles, no glaucomatous optic neuropathy
n=1081
Intervention:
Group 1: Topical Dorzolamide
Group 2: Placebo
The mean IOP declined 22% in the treatment and 19% in the placebo group.
The cumulative probability of converting to an efficacy end point (visual field or optic disc changes) was 13.4% in the dorzolamide group and 14.1% in the placebo group
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive